You have full access to this article via your institution. The authors suggest that screening for NPM1 mutations will be useful for risk assessment in patients with newly diagnosed AML.

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a potentially unlocking a $3 billion market in the U.S. Kura's pipeline also ...

mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor. The primary endpoint was met ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Other analyses of Black patients found that mutations in NPM1 and NRAS genes were associated with inferior disease-free ...

Secondary-type Mutations in NPM1-mutated AML-MRC With a History of MDS or MDS/MPN Do secondary mutations explain why patients with AML with a history of myelodysplasia-related changes and the NPM1 ...

Syndax has also tested the drug in AML driven by mutations to the NPM1 gene. The company is planning a first half 2025 regulatory submission seeking to expand the drug’s approval to AML driven ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...